Search
  • Within this site
AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.
Back to search results

RECOMBINANT RETINOBLASTOMA-ASSOCIATED PROTEIN 1, POLYPEPTIDES AND CDNA


Technology Application

Regulation of normal and mutant retinoblastoma protein


Detailed Technology Description

Researchers have discovers a nuclear protein in normal human cells called ΓÇ£retinoblastoma-associated protein 1ΓÇØ (RBAP-1), also known as E2F-1, that, based on in vitro evidence, binds directly to the RB pocket of the underphosphorylated form of RB and does not bind to phosphorylated RB or to RB with inactivating mutations. The direct binding of RBAP-1 to RB suggests that RBAP-1 is involved in the RB signal transduction pathway


Supplementary Information

Inventor: KAELIN, William, G., Jr. | FLEMINGTON, Erik | DeCAPRIO, James, A. | SELLERS, William | LIVINGSTON, David, M.
Priority Number: WO1993023539A1
IPC Current: C07K001447 | C07K001618 | C12N001512
Assignee Applicant: Dana-Farber Cancer Institute Inc.
Title: RETINOBLASTOMA-ASSOCIATED PROTEIN 1 cDNA | ADNc DE LA PROTEINE 1 ASSOCIEE AU RETINOBLASTOME
Usefulness: RETINOBLASTOMA-ASSOCIATED PROTEIN 1 cDNA | ADNc DE LA PROTEINE 1 ASSOCIEE AU RETINOBLASTOME
Summary: USE The compsns. and methods can be used in the diagnosis and therapy of diseases involving RB, partic. human tumours. Ligands that alter the activation of a gene by RBAP-1 can be used for therapeutic treatment of individuals that are lacking functional RB. Ligands that selectively disrupt RB binding to VTP can be used for the treatment of individuals suffering from a pathologic disease state, such as cervical carcinoma or a malignancy in which the RB signal transduction pathway has been disrupted.
Novelty: New retinoblastoma-associated protein 1 used to develop methods for diagnosis and therapy of diseases involving retinoblastoma protein, esp. tumours


Industry

Biomedical


Sub Group

DNA/Gene Engineering


Country/Region

USA

For more information, please click Here
Business of IP Asia Forum
Desktop View